CpG Island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer

Journal of Urology

Volumn 179, Issue 2, 2008, Pages 529-535

  Bastian, Patrick J ^a,c   Palapattu, Ganesh S ^a   Yegnasubramanian, Srinivasan ^a   Rogers, Craig G ^a   Lin, Xiaohui ^a   Mangold, Leslie A ^a   Trock, Bruce ^a   Eisenberger, Mario A ^a,b   Partin, Alan W ^a   Nelson, William G ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Glutathione S transferase pi; Neoplasm recurrence, local; Prostate; Prostatic neoplasms; Tumor markers, biological

Indexed keywords

CD44V ANTIGEN; ENDOTHELIN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GLUTATHIONE TRANSFERASE P1; MEMBRANE METALLOENDOPEPTIDASE; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN SYNTHASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; DNA EXTRACTION; DNA ISOLATION; DNA METHYLATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; ADULT; AGED; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 38849165455     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.038     Document Type: Article

References (20)

1. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC et al: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975.
2. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC et al: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005;11:4097.
3. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J et al: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000;60:5941.
4. Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C et al: Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131.
5. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B et al: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037.
6. Woodson K, Hayes R, Wideroff L, Villaruz L and Tangrea J: Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 2003;55:199.
7. Jeronimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, Fonseca D et al: Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004;10:4010.
8. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG et al: Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000;6:1664.
9. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253.
10. Wallner M, Herbst A, Behrens A, Crispin A, Stieber P, Goke B et al: Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res 2006;12:7347.
11. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ and Hoon DS: Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006;66:6111.
12. Mori T, O'Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K et al: Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005;23:9351.
13. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N et al: Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate 2007;67:427.
14. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL et al: Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006;107:1265.
15. Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH and Sun CF: Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma. Cancer Detect Prev 2007;31:59.
16. Yegnasubramanian S, Lin X, Haffner MC, DeMarzo AM and Nelson WG: Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylation. Nucleic Acids Res 2006;34:e19.
17. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Muller SC and von Rucker A: Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007;51:665.
18. Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM et al: Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate 2004;60:25.
19. Karimi M, Johansson S, Stach D, Corcoran M, Grander D, Schalling M et al: LUMA (LUminometric Methylation Assay) -a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res 2006;312:1989.
20. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M et al: Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13:1720.